Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS

• Main Authors: Martin Kaatz (Author), Peter Mohr (Author), Elisabeth Livingstone (Author), Michael Weichenthal (Author), Alexander Kreuter (Author), Claudia Pföhler (Author), Ulrike Leiter (Author), Jens Ulrich (Author), Jochen Sven Utikal (Author), Ralf Gutzmer (Author), Rudolf Herbst (Author), Dirk Schadendorf (Author)
• Format: Book
• Published: Medical Journals Sweden, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally advanced BCC inappropriate for surgery or radio...